Key facts
- ZetaGen Therapeutics’s last known valuation is $180.0M (Jan 2025).
- It has raised $52.5M across 4 recorded rounds; the latest was Early Stage VC ($12.9M) in Jan 2025.
- Notable investors include National Institutes of Health, New York Ventures, AJU IB Investment, JStar Capital, National Institutes of Arthritis and Musculoskeletal Diseases.
- ZetaGen Therapeutics has filed 5 Form Ds with the SEC since 2018, most recently Nov 2025 ($12.9M sold to 35 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for ZetaGen Therapeutics
Funding rounds
4 roundsAbout ZetaGen Therapeutics
Developer of a small molecule-based osteoinductive technology designed to suspend cancer, inhibit pain and regenerate bone. The company's technology can transform the treatment of bone-related injuries, procedures and diseases, suspend cancer growth, alleviate pain and promote bone regeneration, enabling healthcare professionals to encompass several oncological candidates targeting metastatic and primary cancers for breast, lung, prostate and bone sarcomas.
- Sector
- Healthcare
- HQ
- Syracuse, NY, United States
- Founded
- 2015
- Employees
- 9
- Website
- zetagen.com/
- Ownership
- Privately Held (backing)
ZetaGen Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ZetaGen Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ZetaGen Therapeutics in its N-PORT filings yet. We sweep new filings monthly.